Angiotensin II receptor blockade or deletion of vascular endothelial ACE does not prevent vascular dysfunction and remodeling in 20-HETE-dependent hypertension

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 309, Issue 1, 2015, Pages R71-R78

  Garcia, Victor ^a   Joseph, Gregory ^a   Shkolnik, Brian ^a   Ding, Yan ^a   Zhang, Frank Fan ^a   Gotlinger, Katherine ^a   Falck, John R ^b   Dakarapu, Rambabu ^b   Capdevila, Jorge H ^c   Bernstein, Kenneth E ^d   Schwartzman, Michal Laniado ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

20 HETE; ACE; Angiotensin II; Angiotensin converting enzyme; Hypertension; Vascular remodeling

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; 20 HYDROXYICOSATETRAENOIC ACID SYNTHASE; ANDROSTANOLONE; ANGIOTENSIN RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 4A12; DIPEPTIDYL CARBOXYPEPTIDASE; DOXYCYCLINE; ENZYME; GLYCINE DERIVATIVE; LISINOPRIL; LOSARTAN; N (20 HYDROXYEICOSA 6,15 DIENOYL)GLYCINE; UNCLASSIFIED DRUG; 20-HYDROXY-5,8,11,14-EICOSATETRAENOIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYICOSATETRAENOIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; FEMALE; GLOMERULUS; HYPERTENSION; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASCULAR REMODELING; WESTERN BLOTTING; ANIMAL; CHEMICALLY INDUCED; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; ENDOTHELIUM CELL; ENZYMOLOGY; GENETICS; METABOLISM; PATHOPHYSIOLOGY; TIME FACTOR; TRANSGENIC MOUSE;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DIHYDROTESTOSTERONE; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HYDROXYEICOSATETRAENOIC ACIDS; HYPERTENSION; MALE; MICE, TRANSGENIC; MICROVESSELS; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM; TIME FACTORS; VASCULAR REMODELING;

EID: 84935449266     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00039.2015     Document Type: Article

References (38)

1. Chen L, Ackerman R, Saleh M, Gotlinger KH, Kessler M, Mende-lowitz LG, Falck JR, Arbab AS, Scicli AG, Schwartzman ML, Yang J, Guo AM. 20-HETE regulates the angiogenic functions of human endothelial progenitor cells and contributes to angiogenesis in vivo. J Pharmacol Exp Ther 348: 442–451, 2014.
2. Cheng J, Edin ML, Hoopes SL, Li H, Bradbury JA, Graves JP, DeGraff LM, Lih FB, Garcia V, Shaik JS, Tomer KB, Flake GP, Falck JR, Lee CR, Poloyac SM, Schwartzman ML, Zeldin DC. Vascular characterization of mice with endothelial expression of cytochrome P450 4F2. FASEB J 28: 2915–2931, 2014.
3. Cheng J, Garcia V, Ding Y, Wu CC, Thakar K, Falck JR, Ramu E, Schwartzman ML. Induction of angiotensin-converting enzyme and activation of the renin-angiotensin system contribute to 20-hydroxyeico-satetraenoic acid-mediated endothelial dysfunction. Arterioscler Thromb Vasc Biol 32: 1917–1924, 2012.
4. Cheng J, Wu CC, Gotlinger KH, Zhang F, Narsimhaswamy D, Falck JR, Schwartzman ML. 20-HETE mediates endothelial dysfunction via Ikk-dependent ENOS uncoupling. J Pharmacol Exp Ther 332: 57–65, 2009.
5. Cole J, Quach DL, Sundaram K, Corvol P, Capecchi MR, Bernstein KE. Mice lacking endothelial angiotensin-converting enzyme have a normal blood pressure. Circ Res 90: 87–92, 2002.
6. Ding Y, Wu CC, Garcia V, Dimitrova I, Weidenhammer A, Joseph G, Zhang F, Manthati VL, Falck JR, Capdevila JH, Schwartzman ML. 20-HETE induces remodeling of renal resistance arteries independent of blood pressure elevation in hypertension. Am J Physiol Renal Physiol 305: F753–F763, 2013.
7. Dunn KM, Renic M, Flasch AK, Harder DR, Falck J, Roman RJ. Elevated production of 20-HETE in the cerebral vasculature contributes to severity of ischemic stroke and oxidative stress in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 295: H2455–H2465, 2008.
8. Eberhardt W, Pfeilschifter J. Nitric oxide and vascular remodeling: spotlight on the kidney. Kidney Int Suppl 106: S9–S16, 2007.
9. Garcia V, Cheng J, Weidenhammer A, Ding Y, Wu C, Zhang F, Gotlinger K, Falck JR, Schwartzman ML. Androgen-induced hypertension in angiotensinogen-deficient mice: Role of 20-HETE and EETS. Prostaglandins Other Lipid Mediat 116–117: 124–130, 2015.
10. Grassi G, Schiffrin EL. Media-to-lumen ratio as predictor of renal abnormalities in hypertension: new findings, new questions. J Hypertens 28: 1811–1813, 2010.
11. Harder DR, Roman RJ. Endothelial dysfunction and hypertension in rats transduced with CYP4A2 adenovirus. Circ Res 98: 866–867, 2006.
12. Heeneman S, Sluimer JC, Daemen MJ. Angiotensin-converting enzyme and vascular remodeling. Circ Res 101: 441–454, 2007.
13. Hercule HC, Oyekan AO. Cytochrome P450 omega/omega-1 hydroxy-lase-derived eicosanoids contribute to endothelin(A) and endothelin(B) receptor-mediated vasoconstriction to endothelin-1 in the rat preglomeru-lar arteriole. J Pharmacol Exp Ther 292: 1153–1160, 2000
14. Holla VR, Adas F, Imig JD, Zhao X, Price E, Olsen N, Kovacs WJ, Magnuson MA, Keeney DS, Breyer MD, Falck JR, Waterman MR, Capdevila JH. Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. Proc Natl Acad Sci USA 98: 5211–5216, 2001.
15. Inoue K, Sodhi K, Puri N, Gotlinger KH, Cao J, Rezzani R, Falck JR, Abraham NG, Laniado-Schwartzman M. Endothelial-specific CYP4A2 overexpression leads to renal injury and hypertension via increased production of 20-HETE. Am J Physiol Renal Physiol 297: F875-F884, 2009.
16. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 38: 581-587, 2001.
17. Ishizuka T, Cheng J, Singh H, Vitto MD, Manthati VL, Falck JR, Laniado-Schwartzman M. 20-Hydroxyeicosatetraenoic acid stimulates nuclear factor- kB activation and the production of inflammatory cytokines in human endothelial cells. J Pharmacol Exp Ther 324: 103-110, 2008.
18. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 59: 251-287, 2007.
19. Lima R, Yanes LL, Davis DD, Reckelhoff JF. Roles played by 20-HETE, angiotensin II and endothelin in mediating the hypertension in aging female spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol 304: R248-R251, 2013.
20. Ljuca F, Drevensek, G. Endothelin-1 induced vascular smooth muscle cell proliferation is mediated by cytochrome p-450 arachidonic acid metabolites. Bosn J Basic Med Sci 10: 223-226, 2010.
21. Miyata N, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. J Smooth Muscle Res 41: 175-193, 2005.
22. Muller DN, Schmidt C, Barbosa-Sicard E, Wellner M, Gross V, Hercule H, Markovic M, Honeck H, Luft FC, Schunck WH. Mouse Cyp4a isoforms: enzymatic properties, gender- and strain-specific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation. Biochem J 403: 109-118, 2007.
23. Nakagawa K, Holla VR, Wei Y, Wang WH, Gatica A, Wei S, Mei S, Miller CM, Cha DR, Price E, Zent R, Pozzi A, Breyer MD, Guan Y, Falck JR, Waterman MR, Capdevila JH. Salt-sensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epithelial sodium channel. J Clin Invest 116: 1696-1702, 2006.
24. Schiffrin EL. Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment. Am J Hypertens 17:1192-1200, 2004.
25. Schiffrin EL, Touyz RM. From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am J Physiol Heart Circ Physiol 287: H435-H446, 2004.
26. Singh H, Cheng J, Deng H, Kemp R, Ishizuka T, Nasjletti A, Schwartzman ML. Vascular cytochrome P450 4A expression and 20-hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction in androgen-induced hypertension. Hypertension 50: 123-129, 2007.
27. Singh H, Cheng J, Deng H, Kemp R, Ishizuka T, Nasjletti A, Schwartzman ML. Vascular cytochrome P450 4A expression and 20-hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction in androgen-induced hypertension. Hypertension 50: 123-129, 2007.
28. Singh H, Schwartzman ML. Renal vascular cytochrome P450-derived eicosanoids in androgen-induced hypertension. Pharmacol Rep 60: 29-37, 2008.
29. Skott O. Androgen-induced activation of 20-HETE production may contribute to gender differences in blood pressure regulation. Am J Physiol Regul Integr Comp Physiol 284: R1053-R1054, 2003.
30. Sodhi K, Wu CC, Cheng J, Gotlinger K, Inoue K, Goli M, Falck JR, Abraham NG, Schwartzman ML. CYP4A2-induced hypertension is 20-hydroxyeicosatetraenoic acid- and angiotensin II-dependent. Hypertension 56: 871-878, 2010.
31. Speed JS, George EM, Arany M, Cockrell K, Granger JP. Role of 20-hydroxyeicosatetraenoic acid in mediating hypertension in response to chronic renal medullary endothelin type B receptor blockade. PLoS One 6: e26063, 2011.
32. Tsai IJ, Croft K, Puddey IB, Beilin LJ, Barden AE. 20-Hydroxyeicosatetraenoic acid synthesis is increased in human neutrophils and platelets by angiotensin ii and endothelin-1. Am J Physiol Heart Circ Physiol 300: H1194-H1200, 2011.
33. Wang JS, Singh H, Zhang F, Ishizuka T, Deng H, Kemp R, Wolin MS, Hintze TH, Abraham NG, Nasjletti A, Laniado-Schwartzman M. Endothelial dysfunction and hypertension in rats transduced with CYP4A2 adenovirus. Circ Res 98: 962-969, 2006.
34. Williams JM, Murphy S, Burke M, Roman RJ. 20-hydroxyeicosatet-raeonic acid: a new target for the treatment of hypertension. J Cardiovasc Pharmacol 56: 336-344, 2010.
35. Wu CC, Cheng J, Zhang FF, Gotlinger KH, Kelkar M, Zhang Y, Jat JL, Falck JR, Schwartzman ML. Androgen-dependent hypertension is mediated by 20-Hydroxy-5,8,11,14-eicosatetraenoic acid-induced vascular dysfunction: role of inhibitor of kB kinase. Hypertension 57: 788-794, 2011.
36. Wu CC, Gupta T, Garcia V, Ding Y, Schwartzman ML. 20-HETE and blood pressure regulation: clinical implications. Cardiol Rev 22: 1-12, 2014.
37. Wu CC, Mei S, Cheng J, Ding Y, Weidenhammer A, Garcia V, Zhang F, Gotlinger K, Manthati VL, Falck JR, Capdevila JH, Schwartzman ML. Androgen-sensitive hypertension associates with upregulated vascular CYP4A12-20-HETE synthase. J Am Soc Nephrol 24: 1288-1296, 2013.
38. Wu CC, Schwartzman ML. The role of 20-HETE in androgen-mediated hypertension. Prostaglandins Other Lipid Mediat 96: 45-53, 2011.